GlassScriptPhysician profile
Christopher M Manus
NPI 1629282389
$2,692.15
in general payments reported to CMS, 2019-2025
30 companies · $675 in 2025
The $675 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $163 · 2021: $237 · 2022: $412 · 2023: $517 · 2024: $406 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $942 · Education: $656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $942.44 |
| Education | $655.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $699.35 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $381.41 | 2021-2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $184.40 | 2019-2025 | Imfinzi, Enhertu |
| Genzyme Corporation | $155.07 | 2019-2025 | |
| Amgen INC. | $112.79 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Gilead Sciences, INC. | $100.62 | 2019-2023 | Trodelvy |
| Exelixis INC. | $81.99 | 2023 | |
| Daiichi Sankyo INC. | $77.29 | 2021-2023 | Enhertu |
| Celgene Corporation | $76.99 | 2021-2023 | Reblozyl |
| Janssen Scientific Affairs, LLC | $76.72 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $74.76 | 2022-2024 | Libtayo |
| Seagen INC. | $70.96 | 2021-2023 | Adcetris |
| Bayer Healthcare Pharmaceuticals INC. | $66.86 | 2019-2025 | |
| Abbvie INC. | $60.80 | 2020-2025 | |
| Taiho Oncology, INC. | $51.16 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $49.97 | 2020-2021 | |
| Myovant Sciences INC. | $47.86 | 2021-2022 | |
| Astellas Pharma US INC | $44.72 | 2019-2024 | |
| Emd Serono, INC. | $41.90 | 2023 | Bavencio |
| Genentech USA, INC. | $32.92 | 2020-2024 | Polivy, Lunsumio, Columvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.54 | 2022 | |
| Janssen Biotech, INC. | $27.86 | 2025 | Rybrevant |
| Merck Sharp & Dohme LLC | $25.66 | 2022-2024 | Welireg, Keytruda, Lynparza |
| Eisai INC. | $22.55 | 2024 | |
| Puma Biotechnology, INC. | $18.66 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $17.70 | 2022 | |
| Agios Pharmaceuticals, INC. | $16.46 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $16.23 | 2024 | Tazverik, Onivyde |
| Sun Pharmaceutical Industries INC. | $14.98 | 2019 | |
| Acrotech Biopharma INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Manus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.